TSX | NYSE: ACB
Appoints Carey Squires as Executive Vice President, Corporate Development & Strategy
Aurora Cannabis Inc. (the “Company” or “Aurora”) (NYSE:ACB) (TSX:ACB.TO) today announced that the Company has appointed Carey Squires as its Executive Vice President of Corporate Development and Strategy. In this newly created role, reporting to the Executive Chairman, Mr. Squires in collaboration with senior executives across the company will focus on global growth and partnership strategies and investor development.
Mr. Squires comes to Aurora with global investment banking experience, having most recently served as Managing Director and Co-Head of Equity-Linked Capital Markets for BMO Capital Markets. In this role, he successfully led the financing for a number of issuers, including Aurora’s recent convertible notes offering. Mr. Squires received a B.Sc from the University of British Columbia as well as an MBA from the Rotman School of Management at the University of Toronto.
“With deep experience in the U.S. and Canadian capital markets, Carey has been a trusted advisor to Aurora on a variety of growth initiatives, including our recently successful capital raise,” said Michael Singer, Executive Chairman of Aurora. “In this new position, Carey will be a core member of Aurora’s senior management team, executing on the development of key strategic initiatives, including partnerships and M&A opportunities. We look forward to working closely with Carey to leverage his extensive knowledge in the execution of our investor development, international growth and partnership strategies, sourcing potential accretive opportunities in the global cannabis industry and negotiating favourable business transactions.”
Headquartered in Edmonton, Alberta, Canada with funded capacity in excess of 500,000 kg per annum and sales and operations in 24 countries across five continents, Aurora is one of the world’s largest and leading cannabis companies. Aurora is vertically integrated and horizontally diversified across every key segment of the value chain, from facility engineering and design to cannabis breeding and genetics research, cannabis and hemp production, derivatives, high value-add product development, home cultivation, wholesale and retail distribution.
Highly differentiated from its peers, Aurora has established a uniquely advanced, consistent and efficient production strategy, based on purpose-built facilities that integrate leading-edge technologies across all processes, defined by extensive automation and customization, resulting in the massive scale production of high quality product at low cost. Intended to be replicable and scalable globally, our production facilities are designed to produce cannabis of significant scale, with high quality, industry-leading yields, and low per gram production costs. Each of Aurora’s facilities is built to meet EU GMP standards, and its first production facility, the recently acquired MedReleaf Markham facility, and its wholly owned European medical cannabis distributor Aurora Deutschland have achieved this level of certification.
In addition to the Company’s rapid organic growth and strong execution on strategic M&A, which to date includes 15 wholly owned subsidiary companies – MedReleaf, CanvasRX, Peloton Pharmaceutical, Aurora Deutschland, H2 Biopharma, Urban Cultivator, BC Northern Lights, Larssen Greenhouses, CanniMed Therapeutics, Anandia Labs, HotHouse Consulting, MED Colombia, Agropro, Borela, and ICC Labs – Aurora is distinguished by its reputation as a partner and employer of choice in the global cannabis sector, having invested in and established strategic partnerships with a range of leading innovators, including: Radient Technologies Inc. (TSXV:RTI.VN), Hempco Food and Fiber Inc. (TSXV:HEMP.VN), Cann Group Ltd. (ASX:CAN), Micron Waste Technologies Inc. (CNSX:MWM.CN), Choom Holdings Inc. (CNSX:CHOO.CN), Capcium Inc. (private), Evio Beauty Group (private), Wagner Dimas (private), CTT Pharmaceuticals (OTCC:CTTH), Alcanna Inc. (TSX:CLIQ.TO) and High Tide Inc. (CNSX:HITI.CN).
Aurora’s Common Shares trade on the TSX and NYSE under the symbol “ACB”, and are a constituent of the S&P/TSX Composite Index.
For more information about Aurora, please visit our investor website, investor.auroramj.com
Neither the TSX, NYSE nor their Regulation Services Provider (as that term is defined in the policies of the TSX and NYSE) accepts responsibility for the adequacy or accuracy of this release.
Terry Booth, CEOAurora Cannabis Inc.
This news release includes statements containing certain “forward-looking information” within the meaning of applicable securities law (“forward-looking statements”), including, but not limited to, statements with respect to the performance of the Company. Forward-looking statements are frequently characterized by words such as “plan”, “continue”, “expect”, “project”, “intend”, “believe”, “anticipate”, “estimate”, “may”, “will”, “potential”, “proposed” and other similar words, or statements that certain events or conditions “may” or “will” occur. These statements are only predictions. Various assumptions were used in drawing the conclusions or making the projections contained in the forward-looking statements throughout this news release. Forward-looking statements are based on the opinions and estimates of management at the date the statements are made, and are subject to a variety of risks and uncertainties and other factors that could cause actual events or results to differ materially from those projected in the forward-looking statements. The Company is under no obligation, and expressly disclaims any intention or obligation, to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as expressly required by applicable law.
View original content to download multimedia:http://www.prnewswire.com/news-releases/aurora-cannabis-expands-management-team-to-support-strategic-initiatives-300824452.html
SOURCE Aurora Cannabis Inc.